Department of Diagnostic Radiology, Fukuiken Saiseikai Hospital, 7-1 Funabashi, Wadanaka-cho, Fuku 918-8503, Japan.
Cardiovasc Intervent Radiol. 2010 Dec;33(6):1168-79. doi: 10.1007/s00270-009-9781-6. Epub 2010 Jan 8.
The purpose of this study was to evaluate the clinical course of main bile duct stricture at the hepatic hilum after transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). Among 446 consecutive patients with HCC treated by TACE, main bile duct stricture developed in 18 (4.0%). All imaging and laboratory data, treatment course, and outcomes were retrospectively analyzed. All patients had 1 to 2 tumors measuring 10 to 100 mm in diameter (mean ± SD 24.5 ± 5.4 mm) near the hepatic hilum fed by the caudate arterial branch (A1) and/or medial segmental artery (A4) of the liver. During the TACE procedure that caused bile duct injury, A1 was embolized in 8, A4 was embolized in 5, and both were embolized in 5 patients. Nine patients (50.0%) had a history of TACE in either A1 or A4. Iodized oil accumulation in the bile duct wall was seen in all patients on computed tomography obtained 1 week later. Bile duct dilatation caused by main bile duct stricture developed in both lobes (n = 9), in the right lobe (n = 3), in the left lobe (n = 4), in segment (S) 2 (n = 1), and in S3 (n = 1). Serum levels of alkaline phosphatase and γ-glutamyltranspeptidase increased in 13 patients. Biloma requiring drainage developed in 2 patients; jaundice developed in 4 patients; and metallic stents were placed in 3 patients. Complications after additional TACE sessions, including biloma (n = 3) and/or jaundice (n = 5), occurred in 7 patients and were treated by additional intervention, including metallic stent placement in 2 patients. After initial TACE of A1 and/or A4, 8 patients (44.4%), including 5 with uncontrollable jaundice or cholangitis, died at 37.9 ± 34.9 months after TACE, and 10 (55.6%) have survived for 38.4 ± 37.9 months. Selective TACE of A1 and/or A4 carries a risk of main bile duct stricture at the hepatic hilum. Biloma and jaundice are serious complications associated with bile duct strictures.
本研究旨在评估经导管动脉化疗栓塞(TACE)治疗肝细胞癌(HCC)后肝门部主胆管狭窄的临床过程。在 446 例接受 TACE 治疗的 HCC 连续患者中,18 例(4.0%)出现主胆管狭窄。回顾性分析所有影像学和实验室数据、治疗过程和结局。所有患者均有 1 至 2 个位于肝门附近的肿瘤,直径为 10 至 100mm(平均 ± SD 24.5 ± 5.4mm),由尾状叶动脉分支(A1)和/或内侧段动脉(A4)供血。在导致胆管损伤的 TACE 过程中,8 例患者 A1 栓塞,5 例患者 A4 栓塞,5 例患者同时栓塞 A1 和 A4。9 例(50.0%)患者 A1 或 A4 有 TACE 史。所有患者在 TACE 后 1 周行 CT 检查均可见胆管壁碘化油蓄积。主胆管狭窄导致双侧胆管扩张(n=9),右叶(n=3),左叶(n=4),S2 段(n=1)和 S3 段(n=1)。13 例患者碱性磷酸酶和γ-谷氨酰转肽酶血清水平升高。2 例患者出现胆汁瘤需引流;4 例患者出现黄疸;3 例患者放置金属支架。在 7 例患者中,在进行额外的 TACE 治疗后出现并发症,包括胆汁瘤(n=3)和/或黄疸(n=5),并通过包括 2 例患者放置金属支架在内的额外介入治疗进行治疗。在初始 TACE 治疗 A1 和/或 A4 后,8 例(44.4%)患者包括 5 例不可控制的黄疸或胆管炎患者,在 TACE 后 37.9±34.9 个月死亡,10 例(55.6%)患者存活 38.4±37.9 个月。选择性 TACE 治疗 A1 和/或 A4 存在肝门部主胆管狭窄的风险。胆汁瘤和黄疸是与胆管狭窄相关的严重并发症。